University of Washington
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).
University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.
University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.
Top-decile sponsor footprint
University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,048 total, page 14 of 21
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
NCT01908101
Body-oriented Therapy for Women in SUD Treatment
NCT01960036
Healthy Families to Change Obesity in Public Housing Residents
NCT03111680
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
NCT02109822
Games to Overcome Late Life Depression
NCT02229188
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
NCT01378273
TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI
NCT02214212
Increasing Implementation of Evidence-based Interventions at Low-wage Worksites
NCT02005497
TEAMcare for Diabetes in Mental Health Centers
NCT02011529
Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms
NCT01892124
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy
NCT01957514
Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women
NCT01849029
Trial of Inserting Prevalence Information Into Lumbar Spine Imaging Reports
NCT02015455
Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach
NCT02164370
Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain
NCT02012439
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
NCT01938573
Clinical Benefits of B-Flow Ultrasound
NCT02008097
Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis
NCT02260401
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
NCT01874184
Superficial Cervical Plexus Block for Shoulder Pain After Lung Surgery
NCT01550302
Improving Communication About Serious Illness
NCT01933789
Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay
NCT01872819
Harm Reduction With Pharmacotherapy (HaRP)
NCT01932801
Lumbar Puncture and Syphilis Outcome
NCT02031146
On Track: Monitoring Development of Children With Cerebral Palsy or Gross Motor Delay
NCT02391948
Ocular Surface Microbiome
NCT02298881
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
NCT01849770
Cabozantinib in Men With Castration-Resistant Prostate Cancer
NCT01703065
Accommodating for Residual Limb Fluid Volume Change
NCT02124876
Pilot Trial of Opioid Taper Support
NCT01883882
Sumatriptan as Treatment for Post-traumatic Headache
NCT01854385
Goals of Care Communication
NCT02466100
Reducing HIV Stigma for African American Women
NCT01893112
Genetic Polymorphisms & The Risk for Sepsis After Trauma
NCT02021552
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
NCT01686828
Stroke and CPAP Outcome Study: A Sham-controlled Trial of CPAP Among Stroke Rehabilitation Patients
NCT02551757
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT01807091
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
NCT01731912
Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families
NCT03119285
Firsthand ID for Pain Control
NCT01823874
Amitriptyline to Prevent Headache After Traumatic Brain Injury
NCT01856270
Military Continuity Project
NCT01829620
Xylitol Disk Use in Adults With Dry Mouth
NCT01823445
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
NCT01729923
Power Over Pain (POP) Study
NCT01800604
Influence of Socket Volume on Prosthesis Performance
NCT02124915
Project OOPEN: Opioid Overdose Prevention, Education and Intervention
NCT01788306
Effects of a Kappa Agonist on Hot Flashes in Menopausal Women
NCT02070718
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
NCT01620190
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01503229
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 127 |
| Phase 2 | 193 |
| Phase 3 | 39 |
| Phase 4 | 65 |
What is open in the University of Washington pipeline
156 recruiting of 1,048 indexed (15% open); 720 completed (69%).
Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).
Top condition: Depression (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Washington: open-pipeline peers nationwide
Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,048 trials (± recruiting share)
- University of Wisconsin, Madison · 1,039 trials · 15% recruiting
- Bristol-Myers Squibb · 1,025 trials · 7% recruiting
- University of Florida · 1,106 trials · 15% recruiting
- University of North Carolina, Chapel Hill · 1,109 trials · 10% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Arizona State University · 15% recruiting · 187 trials
- Georgetown University · 15% recruiting · 227 trials
Related
What to do with this University of Washington page
1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.
- 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.